Effect of atractylenolide III on interstitial cells of Cajal and C-kit/SCF pathway of rats with loperamide-induced slow transit constipation

Wang, Hao; Yuxia, Gong; Li, Youran; Xu, Min; Yunfe, Gu

doi:10.4314/tjpr.v18i6.8

Cited by 3 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is also known that the interstitial cells of Cajal (ICC), which regulate intestinal motility, are not differentiated, developed, or maintained by loperamide, and this phenomenon results in decreased intestinal motility, leading to constipation (Hao et al 2019). Contraction and relaxation of intestinal smooth muscle cells are reduced by loperamide.…”

Section: Effect Of Vp30-eps or Peps On The Intestinal Transit Ratiomentioning

confidence: 99%

In vivo functional effects of Weissella confusa VP30 exopolysaccharides on loperamide-induced constipation in rats

Park¹,

Lee

Yang³

et al. 2022

Food Sci Biotechnol

View full text Add to dashboard Cite

In our previous work, we characterized the in vitro biofunctionality and evaluated the biosafety of exopolysaccharide (EPS)-producing Weissella confusa VP30 (VP30), newly isolated from healthy children's feces.Since the puri ed EPS (pEPS) from fermented milk with VP30 (VP30-EPS) showed signi cant water holding capacity, it was theorized that its consumption would relieve constipation. In this work, the in vivo functionalities of VP30-EPS and pEPS were evaluated for their effect on constipation using an experimental constipated rat model. Rats were randomly divided into four groups: (i) negative control (PBS administered normal group), (ii) loperamide treated positive control (constipation group), (iii) constipation with loperamide plus VP30-EPS (1 g/kg) and (iv) constipation with loperamide plus pEPS (0.6 g/kg) groups. Loperamide treatment induced animal constipation and signi cantly reduced the frequency of defecation, intestinal transit ratio, and water content of feces. However, all four fecal parameters were improved in both the loperamide plus VP30-EPS and pEPS administered groups as compared to the loperamide treated positive control group. No signi cant changes in dietary intake or serum hepatocellular necrosis maker levels were observed in any experimental group. These results suggest that the addition of VP30-EPS or pEPS potentially improves the functional laxative effects of commercial products. No other published research relating in vivo functional effects of EPS from Weissella spp. on constipation could be identi ed. This study suggests the possibility that VP30-EPS and pEPS can be applied to fermented and/or functional foods to relieve constipation.

show abstract

Section: Effect Of Vp30-eps or Peps On The Intestinal Transit Ratiomentioning

confidence: 99%

In vivo functional effects of Weissella confusa VP30 exopolysaccharides on loperamide-induced constipation in rats

Park¹,

Lee

Yang³

et al. 2022

Food Sci Biotechnol

View full text Add to dashboard Cite

show abstract

Atractylenolides (I, II, and III): a review of their pharmacology and pharmacokinetics

et al. 2021

View full text Add to dashboard Cite

Improvement of loperamide-induced slow transit constipation by Bifidobacterium bifidum G9-1 is mediated by the correction of butyrate production and neurotransmitter profile due to improvement in dysbiosis

Makizaki¹,

Uemoto²,

Yokota³

et al. 2021

PLoS ONE

View full text Add to dashboard Cite

A treatment option for constipation that improves the quality of life is needed since available laxatives do not effectively improve the quality of life in patients with constipation. A significant association between gut dysbiosis and constipation is recognized, suggesting that probiotics may be an important option for management of constipation. The underlying mechanism by which probiotics improve constipation remains unclear. In this study, we aimed to evaluate the effects of the probiotic Bifidobacterium bifidum G9-1 (BBG9-1) on loperamide-induced delayed colonic transit constipation and to elucidate its mechanism of action. First, the effect of BBG9-1 was evaluated in a rat model of constipation induced by subcutaneous administration of loperamide. BBG9-1 improved constipation parameters (number of feces, fecal water content, and fecal hardness) in constipated rats. Next, the relationship of organic acids and neurotransmitters to gut microbiota was investigated. BBG9-1 improved dysbiosis and prevented a decrease in butyric acid concentration in the gut, increased serum serotonin, and suppressed an increase in dopamine and a decrease in acetylcholine in serum. Further, an increase in the expression level of tryptophan hydroxylase 1, a 5-HT-synthetizing enzyme, was observed. These results suggest that BBG9-1 improves dysbiosis, which results in an increase in organic acids and improvement of neurotransmission. These actions may increase intestinal mobility, finally leading to alleviating constipation. The probiotic BBG9-1 may, therefore, be a potential option for the treatment of constipation.

show abstract

Effect of atractylenolide III on interstitial cells of Cajal and C-kit/SCF pathway of rats with loperamide-induced slow transit constipation

Cited by 3 publications

References 23 publications

In vivo functional effects of Weissella confusa VP30 exopolysaccharides on loperamide-induced constipation in rats

In vivo functional effects of Weissella confusa VP30 exopolysaccharides on loperamide-induced constipation in rats

Atractylenolides (I, II, and III): a review of their pharmacology and pharmacokinetics

Improvement of loperamide-induced slow transit constipation by Bifidobacterium bifidum G9-1 is mediated by the correction of butyrate production and neurotransmitter profile due to improvement in dysbiosis

Contact Info

Product

Resources

About